{"id":"chf5993-pmdi","safety":{"commonSideEffects":[{"rate":"10-20%","effect":"Oral thrush"},{"rate":"5-10%","effect":"Headache"},{"rate":"5-10%","effect":"Cough"},{"rate":"5-10%","effect":"Sore throat"},{"rate":"5-10%","effect":"Nausea"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"It works by reducing inflammation in the lungs, making it easier to breathe. CHF5993 pMDI is a dry powder inhaler that delivers a precise dose of the corticosteroid to the lungs, where it can be most effective.","oneSentence":"CHF5993 pMDI is a corticosteroid inhalation powder for the maintenance treatment of asthma and the treatment of chronic obstructive pulmonary disease (COPD).","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T03:26:19.453Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Maintenance treatment of asthma"},{"name":"Treatment of chronic obstructive pulmonary disease (COPD)"}]},"trialDetails":[{"nctId":"NCT04320342","phase":"PHASE3","title":"A Study Comparing Efficacy, Safety and Tolerability of the Fixed Dose Triple Combination CHF 5993 With the Fixed Dose Dual Combination CHF 1535 in Subjects With COPD","status":"COMPLETED","sponsor":"Chiesi Farmaceutici S.p.A.","startDate":"2022-04-28","conditions":"COPD, COPD Exacerbation","enrollment":3433},{"nctId":"NCT07301736","phase":"PHASE2","title":"Therapeutic Equivalence of CHF5993 pMDI 100/6/12.5 µg HFA-152a in Subjects With Mild to Moderate Asthma","status":"RECRUITING","sponsor":"Chiesi Farmaceutici S.p.A.","startDate":"2025-12-17","conditions":"Asthma","enrollment":780},{"nctId":"NCT06264674","phase":"PHASE3","title":"Comparison Between CHF5993 pMDI 200/6/12.5 µg HFA-152a VS CHF5993 pMDI 200/6/12.5 µg HFA-134a in Subjects With Asthma (TRECOS).","status":"COMPLETED","sponsor":"Chiesi Farmaceutici S.p.A.","startDate":"2023-11-27","conditions":"Asthma","enrollment":836},{"nctId":"NCT05018598","phase":"PHASE4","title":"Step-up to Medium Strength Triple Therapy vs High Strength ICS/LABA in Adult Asthmatics Uncontrolled on Medium Strength ICS/LABA","status":"TERMINATED","sponsor":"Chiesi Farmaceutici S.p.A.","startDate":"2022-02-25","conditions":"Asthma","enrollment":320},{"nctId":"NCT05898984","phase":"PHASE1","title":"Clinical Study to Evaluate the Safety, Tolerability and the Concentration of the BDP (Beclomethasone Dipropionate), Active Metabolite of BDP, FF( Formoterol Fumarate) and GB (Glycopyrronium Bromide), After Inhalation of CHF 5993 at Two Different Doses and QVAR®","status":"COMPLETED","sponsor":"Chiesi Farmaceutici S.p.A.","startDate":"2023-04-24","conditions":"Asthma","enrollment":69},{"nctId":"NCT05830071","phase":"PHASE1","title":"A Thorough QT (TQT) Study of CHF5993 pMDI in Healthy Volunteers (HV)","status":"COMPLETED","sponsor":"Chiesi Farmaceutici S.p.A.","startDate":"2023-03-29","conditions":"Asthma, Chronic Obstructive Pulmonary Disease (COPD)","enrollment":95},{"nctId":"NCT05097014","phase":"PHASE4","title":"CHF5993 and CHF1535 pMDI on Lung Hyperinflation and Exercise Endurance Time in Subjects With COPD","status":"COMPLETED","sponsor":"Chiesi Farmaceutici S.p.A.","startDate":"2021-10-28","conditions":"Chronic Obstructive Pulmonary Disease","enrollment":106},{"nctId":"NCT02119234","phase":"PHASE1","title":"Pharmacokinetics of CHF 5993 pMDI With and Without Spacer in COPD Patients","status":"COMPLETED","sponsor":"Chiesi Farmaceutici S.p.A.","startDate":"2014-03","conditions":"COPD","enrollment":36},{"nctId":"NCT02287272","phase":"PHASE1","title":"Drug-drug Interaction Study of CHF5993 With Cimetidine","status":"COMPLETED","sponsor":"Chiesi Farmaceutici S.p.A.","startDate":"2014-05","conditions":"COPD","enrollment":25},{"nctId":"NCT01584505","phase":"PHASE2","title":"Phase II Study to Evaluate the Cardiac Safety of 2 Doses of CHF5993 Both Combined With CHF1535 BID Versus CHF1535 BID in Patients With Moderate to Severe COPD","status":"COMPLETED","sponsor":"Chiesi Farmaceutici S.p.A.","startDate":"2012-04","conditions":"Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD)","enrollment":191},{"nctId":"NCT02467452","phase":"PHASE3","title":"Non Inferiority of Fixed Combination of Beclomethasone Dipropionate (BDP) + Formoterol Fumarate (FF) + Glycopyrronium Bromide (GB) Versus Combination of Fluticasone Furoate (FlF)/Vilanterol (VI) + Tiotropium Bromide in Chronic Obstructive Pulmonary Disease (COPD)","status":"COMPLETED","sponsor":"Chiesi Farmaceutici S.p.A.","startDate":"2015-05","conditions":"Chronic Obstructive Pulmonary Disease","enrollment":1479},{"nctId":"NCT01917331","phase":"PHASE3","title":"Efficacy of Fixed Combination of Beclometasone + Formoterol + Glycopyrrolate Versus Foster® in COPD","status":"COMPLETED","sponsor":"Chiesi Farmaceutici S.p.A.","startDate":"2014-03","conditions":"Chronic Obstructive Pulmonary Disease","enrollment":1368},{"nctId":"NCT01911364","phase":"PHASE3","title":"Efficacy of Fixed Combination of Beclometasone + Formoterol + Glycopyrrolate in Chronic Obstructive Pulmonary Disease","status":"COMPLETED","sponsor":"Chiesi Farmaceutici S.p.A.","startDate":"2014-01","conditions":"Chronic Obstructive Pulmonary Disease","enrollment":3686},{"nctId":"NCT02579850","phase":"PHASE3","title":"2-arm Parallel Group Study of Fixed Combination of CHF 5993 vs Ultibro® in COPD Patients","status":"COMPLETED","sponsor":"Chiesi Farmaceutici S.p.A.","startDate":"2015-05-29","conditions":"Chronic Obstructive Pulmonary Disease (COPD)","enrollment":1532},{"nctId":"NCT02040597","phase":"PHASE1","title":"A Study to Investigate the Pharmacokinetics, Safety and Tolerability of CHF 5993 pMDI in Subjects With Renal Impairment.","status":"COMPLETED","sponsor":"Chiesi Farmaceutici S.p.A.","startDate":"2014-01","conditions":"Chronic Obstructive Pulmonary Disease (COPD)","enrollment":42},{"nctId":"NCT03859414","phase":"PHASE1","title":"PK of BDP/FF/GB Single-inhaler Triple Therapy in Japanese vs. Caucasians","status":"COMPLETED","sponsor":"Chiesi Farmaceutici S.p.A.","startDate":"2019-03-18","conditions":"Asthma, Chronic Obstructive Pulmonary Disease","enrollment":32},{"nctId":"NCT02359292","phase":"PHASE1","title":"Clinical Pharmacology Study to Evaluate the Total Systemic Exposure and Lung Bioavailability of CHF 5993 pMDI Combination in Healthy Volunteers","status":"COMPLETED","sponsor":"Chiesi Farmaceutici S.p.A.","startDate":"2015-02","conditions":"Asthma","enrollment":50},{"nctId":"NCT02743013","phase":"PHASE1","title":"Clinical Pharmacology Study to Evaluate the Total Systemic Exposure and the Lung Availability of CHF 5993 in Healthy Volunteers","status":"COMPLETED","sponsor":"Chiesi Farmaceutici S.p.A.","startDate":"2016-04","conditions":"COPD","enrollment":50},{"nctId":"NCT03590379","phase":"PHASE2","title":"Efficacy of Fixed Combination of Beclomethasone Dipropionate (BDP) + Formoterol Fumarate (FF) + Glycopyrronium Bromide (GB) (CHF 5993)Administered Via Dry Powder Inhaler (DPI) in Chronic Obstructive Pulmonary Disease (COPD)","status":"COMPLETED","sponsor":"Chiesi Farmaceutici S.p.A.","startDate":"2018-06-15","conditions":"Chronic Obstructive Pulmonary Disease","enrollment":366},{"nctId":"NCT02676076","phase":"PHASE3","title":"TRIple in asthMA With uncontRolled pAtient on Medium streNgth of ICS + LABA","status":"COMPLETED","sponsor":"Chiesi Farmaceutici S.p.A.","startDate":"2016-02-17","conditions":"Asthma","enrollment":1153},{"nctId":"NCT02676089","phase":"PHASE3","title":"TRIple in Asthma hiGh strenGth vErsus Ics/Laba hs and tiotRopium (TRIGGER)","status":"COMPLETED","sponsor":"Chiesi Farmaceutici S.p.A.","startDate":"2016-04-06","conditions":"Asthma","enrollment":1433},{"nctId":"NCT03197818","phase":"PHASE3","title":"Active Controlled Trial of CHF5993 Pressurized Metered-dose Inhaler ( pMDI) vs Symbicort®Turbuhaler® in Patients With Chronic Obstructive Pulmonary Disease ( COPD)","status":"COMPLETED","sponsor":"Chiesi Farmaceutici S.p.A.","startDate":"2016-12-14","conditions":"COPD (Chronic Obstructive Pulmonary Disease)","enrollment":990},{"nctId":"NCT03268226","phase":"PHASE3","title":"Functional Respiratory Imaging Study (FRI)","status":"COMPLETED","sponsor":"Chiesi Farmaceutici S.p.A.","startDate":"2017-11-20","conditions":"Chronic Obstructive Pulmonary Disease","enrollment":20},{"nctId":"NCT02975843","phase":"PHASE1","title":"Lung Deposition of Beclometasone Dipropionate/Formoterol Fumarate/Glycopyrronium Bromide Administered Via pMDI in Healthy, Asthmatic and COPD Patients","status":"COMPLETED","sponsor":"Chiesi Farmaceutici S.p.A.","startDate":"2016-11-21","conditions":"Chronic Obstructive Pulmonary Disease, Asthma","enrollment":28}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":1080,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_2","status":"active","brandName":"CHF5993 pMDI","genericName":"CHF5993 pMDI","companyName":"Chiesi Farmaceutici S.p.A.","companyId":"chiesi-farmaceutici-s-p-a","modality":"Small molecule","firstApprovalDate":"","aiSummary":"CHF5993 pMDI is a corticosteroid inhalation powder for the maintenance treatment of asthma and the treatment of chronic obstructive pulmonary disease (COPD). Used for Maintenance treatment of asthma, Treatment of chronic obstructive pulmonary disease (COPD).","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}